Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-21
    E.g., 2018-09-21

Archive Search

1 results
12:00 AM, Aug 05, 2013  |  BC Week In Review | Clinical News  |  Clinical Status

AF802: Phase II started

disclosed in its 2Q13 earnings that it began a dose-escalation Phase II trial to evaluate RG7853
Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan   Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland   Product: AF802
CH5424802 , RG7853   Business: Cancer   Molecular target: Anaplastic lymphoma kinase (ALK)   Description …